NEW YORK – Already an established presence in the breast cancer testing space, Hologic’s planned acquisition of Biotheranostics provides an opportunity to further expand its footprint in that market, according to company executives.
Last week, Hologic announced the deal to acquire molecular diagnostics firm Biotheranostics for approximately $230 million.
Get the full story with
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.